News About: Pharm. Affairs
Reduction in bioequivalently-tested drugs shows slowdown in Korean generic development
It was analyzed the number of pharmaceutical products approved by bioequivalence test this year was rapidly decreased to 125 products compared to the same period of the last year.
According to the Ministry of Food an...
Debate to revive excellent Korean drugs, such as generics
The pharmaceutical distribution industry’s ‘Korean Drug Revival Movement’ has met a new phase.
The Minjoo Party Rep. Sae-Jae Oh held the ‘Korean Drug Revival Debate for Development of Pharmaceutical Industry’ at the ...
KPA pushes to prepare amendment to Pharmaceutical Affairs Law for pharmacist students’ field trainings
The Korean Pharmaceutical Association’s(KPA) Special Committee for Pharmacist Education(Vice Chairman in Charge Duk-Sook Yang, Chairman Kyung-Hae Jung) held the 1st Special Committee and Joint Staff Meeting for Field ...
‘Return of disused drugs’ & ‘simplification of generic substitution’ chosen by Seoul Pharmaceutical Association
Member pharmacists in the Seoul area chose ‘public welfare’ and ‘policy’ as the projects for the Seoul Pharmaceutical Association to preferentially carry out.
On the 23rd, the Seoul Pharmaceutical Association(Chairma...
Seoul Pharmaceutical Association, “Government must call off Veterinary Drug Monopolization Policy”
The Seoul Pharmaceutical Association presented a written statement that the extension of veterinary prescription drugs, which will help animal hospitals monopolize veterinary drugs and obstruct patients’ accessibility...
KVPA welcomes Zoetis’s decision to supply heartworm preventives to pharmacies
The Korea Veterinary Pharmacy Association(President Sung-Jin Kim, KVPA) expressed an opinion to welcome the Zoetis Korea’s decision to supply heartworm preventive medicines for pets.
This decision was followed by t...
Abbvie announces acquisition of approval for chronic hepatitis C oral treatment VIEKIRAX/EXVIERA
Abbvie Korea(CEO Hong-Ki Yoo) announced the Korea Ministry of Health and Welfare approved VIEKIRAX(generic name: ombitasvir, paritaprevir, ritonavir) and EXVIERA(generic name: sasabuvir) as chronic hepatitis C treatme...
Why does KPA make fights against each other for the same goal?
As the Korean Pharmaceutical Association(KPA) has face continuous conflicts over the ‘improvement of election system’ issue at the regular representative meeting, the plan practically went vain, which raised strong cr...
1-year ‘satisfactory’ application of insurance benefit for Daklinza for treatment of hepatitis C
After the mass hepatitis C infection incident, the Korea Centers for Disease Control and Prevention(KCDC) recently revealed the reaction of Korean hepatitis C patients to interferon and the effect of treatment after a...
National Assembly’s debate for adjustment of household drugs at convenient stores
While the government has created an issue as trying to adjust the number of emergency household products, it will conduct debates related to it.
The National Assembly Health and Welfare Committee’s Rep. Do-Ja Choi(Pe...
